Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer

Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
Interview conducted on September 6, 2024, by Dr Neil Love. Featuring an interview with Dr Tiffany A Traina. Published September 24, 2024.
Topics:
• Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00)
• Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37)
• Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of treatment-associated side effects (14:34)
• Activity and tolerability of enfortumab vedotin for mTNBC (21:47)
• Rationale for combining antibody-drug conjugates with other systemic therapies for TNBC; early data and ongoing research efforts with combination approaches (24:13)
• Selection and sequencing of therapeutic options for advanced breast cancer (26:36)
• Clinical activity of trastuzumab deruxtecan; spectrum, severity and management of treatment-emergent toxicities (32:00)
• Case: A woman in her early 60s with mTNBC receives first-line pembrolizumab/carboplatin/gemcitabine (35:32)
• Case: A woman in her late 30s with TNBC and a short disease-free interval with adjuvant therapy is found to have CNS metastases that are treated with sacituzumab govitecan (40:40)
• Case: A woman in her late 60s and practicing physician is diagnosed with HR-negative, HER2-low mBC (44:16)
The entire program, slides, CME information, and select publications:
www.researchto...